

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-601

C# M#

HAYNES, Barton F.

DEC 01 2003

Group Art Unit: 1644

Serial No. 09/956,940

Examiner: Schwadron, R.

Filed: September 21, 2001

Date: December 1, 2003

Title: USE OF SYNTHETIC PEPTIDES TO INDUCE TOLERANCE TO PATHOGENIC T
AND B CELL EPITOPES OF AUTOANTIGENS OR INFECTIOUS AGENTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.**

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00) \$ 0.00

☐ Please enter the previously unentered , filed

☐ Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

Mary J. Wilson



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HAYNES, Barton F.

Atty. Ref.: 1579-601; Confirmation No. 4369

Appl. No. 09/956,940

Group: 1644

Filed: September 21, 2001

Examiner: Schwadron, R.

For: USE OF SYNTHETIC PEPTIDES TO INDUCE TOLERANCE TO PATHOGENIC
T AND B CELL EPITOPES OF AUTOANTIGENS OR INFECTIOUS AGENTS

* * * * *

December 1, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Attached are PTO-1449 Forms listing references that are of record in connection with one or more of the applications from which this case claims priority. The Examiner is respectfully requested to initial and return the attached Forms. Should the Examiner require additional copies of any of the listed documents, he is requested to so indicate and same will be provided.

While no official fee is believed to be required, authorization is hereby given to debit the undersigned firm's deposit account (14-1140, Order No. 1579-601) should the Office take a different view.

HAYNES, Barton F.
Appl. No. 09/956,940
December 1, 2003

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

A handwritten signature in cursive script, appearing to read "Mary J. Wilson", written over a horizontal line.

Mary J. Wilson
Reg. No. 32,955

MJW:tat
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No.

Serial No.

1579-601**09/956,940**

Applicant

HAYNES, Bart n F.

Filing Date

Group

Sept mb r 21, 2001**1644**

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,993,819	11/1999	Haynes et al			
	5,019,387	5/1991	Haynes			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 87/02775	5/1987	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Haynes et al, J. Exp. Med. 177:717-727 (1993)
	Nossal, Chapter 19 from Fundamentals of Immunology, Second Edition, Ed. W.E. Paul, Raven Press, pp. 5710585 (1989)
	Fahey et al, Clin. Exp. Immunol. 88:1-9 (1992)
	Jacobson et al, The Journal of Immunology 146:11-55-1162 (1991)
	Hoffmann et al, Proc. Natl. Acad. Sci. USA 88:3060-3064 (1991)
	Wigzell, The FASEB Journal 5:2406-2411 (1991)
	Hart et al, Proc. Natl. Acad. Sci. USA 88:9448-9452 (1991)
	Papadouli et al, Biochem. J. 269:239-245 (1990)
	Mori et al, Biochemical and Biophysical Research Communications 178(1):165-172 (1991)
	Murakami et al, Biochemical and Biophysical Research Communications 171(1):512-518 (1990)
	Offner et al, The Journal of Immunology 141(1):3828-3832 (1988)
	Wucherpfennig et al, Immunology Today 12(8):277-282 (1991)
	Sanui et al, The Journal of Experimental Medicine 169:1947-1960 (1989)
	Grassi et al, J. Exp. Med. 174:53-62 (1991)
	Nature 333:215 (1988)
	Golding et al, Journal of Experimental Medicine 167:914-923 (1988)
	Takai et al, Biochemical and Biophysical Research Communications 179(1):319-326 (1991)
	Piraphatdist et al, Biochemical and Biophysical Communications 172(2):529-536 (1990)
	Hendricks et al, Journal of Immunology 142(1):263-269 (1989)
	Weigel, "Immunogenicity of Protein Antigens: Repertoire and Regulation", Vol. II, Chapter 5G, Sercarz and Berzofsky (Editors), pgs. 51-57
	Gahring et al, The Journal of Immunology 145:1318-1323 (1990)

Other et al, The Law

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Dock # No.

Serial No.

1579-601

09/956,940

Applicant

HAYNES, Bart n F.

Filing Date

Group

Sept mb r 21, 2001

1644



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Milich et al, The Journal of Immunology 143(10):3148-3156 (1989)
	Sprent et al, Science 248:1357-1363 (1990)
	Haynes et al, "Induction of HIVMN Neutralizing Antibodies in Primates Using a Prime-Boost Regimen of Hybrid Synthetic gp120 Envelope Peptides", The Journal of Immunology 151(3):1646-1653 (1993)
	Lee et al, "Suppression of Reaginic Antibodies with Modified Allergens", Int. Archs. Allergy Appl. Immun. 56:159-170 (1978)
	Lee et al, "Suppression of Reaginic Antibodies with Modified Allergens", Int. Archs. Allergy Appl. Immun. 56:193-206 (1978)
	Wie et al, "Suppression of Reaginic Antibodies with Modified Allergens", Int. Archs. Allergy Appl. Immun. 64:84-99 (1981)
	Lee et al, "Suppression of Reaginic Antibodies with Modified Allergens", Int. Archs. Allergy Appl. Immun. 64:100-114 (1981)
	Abuchowski et al, "Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol", The Journal of Biological Chemistry 252(11):3578-3581 (1977)
	Abuchowski et al, "Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase", The Journal of Biological Chemistry 252(11):3582-3586 (1977)
	Abuchowski et al, "Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates", Cancer Biochem. Biophys. 7:175-186 (1984)
	Davis et al, "Soluble, Nonantigenic Polyethylene Glycol-Bound Enzymes", Biomedical Polymers Polymeric Materials and Pharmaceuticals for Biomedical Use", pp. 441-452 (1980)
	Edgington, Bio/Technology 10:383 (1992)
	Takahashi et al, J. of Exp. Med. 170:2023 (198?)
	Palker et al, J. of Immunol. 142:3612 (198?)
	Girard et al, J. of Cell. Biochem. - Abstract L415 (1990) UCLA Symp. on Mol and Cell. Biol. p. 150
	Weinhold et al, J. Cell. Biochem. - Abstract L550 (1990) UCLA Symp. on Mol. and Cell. Biol. p. 180
	Palker et al, J. Cell. Biochem. - Abstrat L315 (1990) UCLA Symp. on Mol. and Cell. Biol. p. 134
	Palker et al, Proc. Natl. Acad. Sci. 85:1932-1936 (1988)
	Gallaher, Cell 50:327-328 (1987)
	Ellis, in Vaccines, Plotkin and Mortimer, eds., W.B. Saunders Co., p. 568-575 (1988)

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No.

1579-601

Applicant

HAYNES, Bart n F.

Filing Date

September 21, 2001

Serial No.

09/956,940

Group

1644

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

*EXAMINER
INITIAL

	Pert et al, "Octapeptides Decuted from the Neuropeptide Receptor-Like Pattern of Antigen T4 in Brain Potently Inhibit Human Immunodeficiency Virus Receptor Binding and T-Cell Infectivity", Proc. Natl. Acad. Sci. USA 83:9254-9258 (1986)
	Sarin et al, "Neutralization of HTLV-III/LAV Replication By Antiserum to Thymosin α_1 ", Science 232:1135-1138 (1986)
	Kennedy et al., "Antiserum to A Synthetic Peptide Recognizes the HTLV-III Envelope Glycoprotein", Science 231:1556-1560 (1986)
	Chanh et al, "Induction of Anti-HIV Neutralizing Antibodies By Synthetic Peptides", The EMBO Journal 5(11):??? (???)
	Putney et al, "HTLV-III/LAV-Neutralizing Antibodies to an E. Coli-Produced Fragment of the Virus Envelope, Science 234:1392-1395 (1986)
	Kennedy et al, "Use of a Resin-Bound Synthetic Peptide for Identifying A Neutralizing Antigenic Determinant Associated with the Human Immunodeficiency Virus Envelope", The Journal of Biological Chemistry 262(12):5769-5774 (1967)
	Cease et al, "Helper T-Cell Antigenic Site Identification in the Acquired Immunodeficiency Syndrome Virus gp120 Envelope Protein and Induction of Immunity in Mice to the Native Portein Using a 16-Residue Synthetic Peptide", Proc. Natl. Acad. Sci. USA 84:4249-4253 (1987)
	Ho et al, "Human Immunodeficiency Virus Neutralizing Antibodies Recognize Several Conserved Domains on the Envelope Glycoproteins", Journal of Virology 61(6):2024-2028 (1987)
	Krohn et al, "Specific Cellular Immune Response and Neutralizing Antibodies in Goats Immunized with Native or Recombinant Envelope Proteins Derived from Human T-Lymphotropic Virus Type III _B and in Human Immunodeficiency Virus-Infected Men", Proc Natl. Acad. Sci. USA 84:4994-4998 (1987)
	Starcich et al, "Identification and Characterization of Conserved and Variable Regions in the Envelope Gene of HTLV-III/LAV, The Retrovirus of AIDS", Cell 45:637-648 (1986)
	Robey et al, "Prospect for Prevention of Human Immunodeficiency Virus Infection: Purified 120-kDa Envelope Glycoprotein Induces Neutralizing Antibody", Proc. Natl Acad. Sci. USA 83:7023-7027 (1986)
	Wang et al, "Detection of Antibodies to Human T-Lymphotropic Virus Type III By Using A synthetic Peptide of 21 Amino Acid Residues Corresponding to a Highly Antigenic Segment of gp41 Envelope Protein", Proc. Natl. Acad. Sci. USA 83:6159-6163 (1986)
	Sodroski et al, "Role of the HTLV-III/LAV Envelope in Syncytium Formation and Cytopathicity", Nature 322:470-474 (1986)
	Dalglish et al, "The CD4 (T4) Antigen is an Essential Component of the Receptor for the AIDS Retrovirus", Nature 312:763-767 (1984)
	Hu et al, "Expression of AIDS Virus Envelope Gene in Recombinant Vaccinia Viruses", Nature 320:??? (1986)
	Chakrabarti et al, "Expression of the HTLV-III Envelope Gene by a Recombinant Vaccinia Virus", Nature 320:535-540 (1986)
	Zarling et al, "Proliferative and Cytotoxic T Cells to AIDS Virus Glycoproteins in Chimpanzees Immunized with a Recombinant Vaccinia Virus Expressing AIDS Virus Envelope Glycoproteins", The Journal of Immunology 139:988-990 (1987)
	Hu et al, "Effect of Immunization with a Vaccinia-HIV <i>env</i> Recombinant on HIV Infection of Chimpanzees", Nature 328:721-723 (1987)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

(Use several sheets if necessary)

1579-601

HAYNES,

S p t m b e r

09/956,940

1644

U.S. PATENT DOCUMENTS

*EXAMINER
INITIAL

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Ratner et al, "Complete nucleotide sequence of the AIDS virus, HTLV-III", Nature 313:277-284 (1985)

Newmark, Peter, "Problems with AIDS Vaccines", *Nature* 324:304-305 (1986)

Norman, Colin, "AIDS Virus Presents Moving Target", Science 230:1357-1358 (1985)

Palker et al, "The conserved region at the COOH terminus human immunodeficiency virus gp120 envelop protein contains as in immunodominant epitope", Proc. Natl. Acad. Sci. USA 84:2479-2483 (1987)

***Examiner**

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.